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Human milk oligosaccharides (HMO) are major components of breast milk that may have
local effects in the gastrointestinal tract and systemic functions after being absorbed,
both depending on their metabolism. Using preterm pigs, we investigated the metabolic
fate of HMO in three experiments with two different HMO blends. In addition, we
examined effects on the colonic microbiota in the presence or absence of necrotizing
enterocolitis (NEC). Thus, preterm pigs (n = 112) were fed formula without or with
HMO supplementation (5–10) g/L of a mixture of 4 (4-HMO) or >25 HMO (25-HMO)
for 5 (Experiment 1 and 2) or 11 days (Experiment 3). Individual HMO were quantified
in colon contents and urine using MALDI-TOF-MS (matrix-assisted laser desorption
ionization mass spectrometry) and HPAEC-PAD (high-performance anion-exchange
chromatography with pulsed amperometric detection). Microbial colonization was
analyzed by sequencing of 16S rRNA gene tags. Intestinal permeability was measured by
lactulose to mannitol ratio in urine. HMO supplemented to formula were detected in urine
and colon contents in preterm piglets after 5 and 11 days in all three experiments. The
amount of HMO excreted via the gut or the kidneys showed large individual variations.
Microbial diversity in the colon changed from high levels of Firmicutes (dominated by
Clostridium) at day 5 (Exp 2) to high levels of Proteobacteria dominated by Helicobacter
and Campylobacter at day 11 (Exp 3). Colonic microbiota composition as well as HMO
excretion pattern varied greatly among piglets. Interestingly, the 5-day supplementation
of the complex 25-HMO blend led to low concentrations of 3-fucosyllactose (FL) and
lacto-N-fucopentaose (LNFP) I in colonic contents, indicating a preferred utilization of
these two HMO. Although the interpretation of the data from our piglet study is difficult
due to the large individual variation, the presence of Bifidobacteria, although low in total
numbers, was correlated with total HMO contents, and specifically with 2′FL levels in
colonic content. However, early supplementation of formula with HMO did not affect
NEC incidence.
Keywords: human milk oligosaccharides (HMO), preterm pigs, metabolism, necrotizing enterocolitis (NEC),
microbiota, formula
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INTRODUCTION
Increasing evidence supports the hypothesis that benefits of
human milk for infants are partly explained by the abundance
of complex oligosaccharides. Proposed functions concern their
interactions with gut microbiota, the prevention of pathogen
adhesion to the epithelium, effects on gut maturation or an
influence on the developing brain (1–7). So far, the first human
trials with one or two single human milk oligosaccharides
(HMO), 2′fucosyllactose (FL) or 2′FL plus lacto-N-neo-tetraose
(LNnT), in term infants demonstrated that the new formula
were safe and lead to growth rates comparable to those
found in term human milk-fed infants (8, 9). Within this
context, metabolic aspects of HMO are an important issue
as, for example, currently discussed systemic effects such as
an influence on inflammatory processes or on brain functions
and activity require the preceding absorption of HMO. Indeed,
HMO have been detected in the circulation of breast-fed
infants (10, 11). To investigate metabolic pathways of single
HMOs, studies in infants are limited due to the low HMO
availability and also for ethical concerns. Therefore, the selection
of an appropriate alternative animal model is an important
point to consider. In animals, it has been shown that some
HMO can be absorbed (12, 13). As rats, however, do not
seem to be suitable for HMO metabolic studies, we used
pigs which may have a translational advantage based on the
physiological similarity between pigs and humans with regard to
the gastrointestinal tract, its delayed maturation and high natural
sensitivity to necrotizing enterocolitis (NEC) after preterm
birth (14, 15).
In preterm infants, NEC is a major cause of morbidity
and mortality affecting 5–10% of infants <1,500 g with a
mortality of 20–30% (16, 17). Breast-fed infants were shown
to have lower NEC incidences than formula-fed infants (18).
In rat pups, three studies showed that the addition of
HMO such as disialyl-lacto-N-tetraose (DSLNT), 2′FL or 2′FL
plus sialylated galactooligosaccharides, the latter not being
present in human milk, decreased NEC incidence (19–21).
A potential mechanism for the observed effects may be
the upregulation of mucins, and concomitant decrease in
intestinal permeability which has recently been shown by pooled
HMO (22).
We hypothesized that HMO supplementation of formula
leads to fecal and/or urinary excretion of intact HMO at
various amounts depending on the prevailing microbiota. If
so, not only gastrointestinal but also systemic functions are to
be expected. In addition, we aimed at investigating whether
HMO supplemented formula affect bacterial colonization and
thereby improve NEC resistance in preterm pigs. Because of
the potential for synergistic effects among different HMO, we
investigated for the first time effects of a large range of HMO,
e.g., mixtures containing either 4 or >25 HMO, the latter
reflecting the complex oligosaccharide composition in human
milk. Clinical and physiological effects on the gastrointestinal
tract have been reported previously (23). Here, we focus
on HMO metabolism and its potential relations to bacterial
gut colonization.
MATERIALS AND METHODS
Information on animal housing is given in the preceeding paper
(19). The HMO blends were provided by Glycom A/S (Lyngby,
Denmark). The study was approved by the Danish National
Committee on Animal Experimentation (license number 2012-
15-2934-00193).
Experimental Design and
Sample Collection
Experiment 1, 2, and 3 were carried out in preterm born pigs
(delivered by Cesarean section at ∼90% of gestation) using
different blends of HMO and varying length of exposure time (5
or 11 days postpartum) as described previously (Figure 1) (23).
HMO blends were chosen to either represent the most abundant
individual structures in human milk (4-HMO) or to additionally
cover more closely the complex range of oligosaccharides known
for human milk with more than 25 compounds present (25-
HMO) (Table 1).
Preterm pigs (n = 112) in each of the three experiments were
divided into two groups (control and HMO-treated) based on
birth weight and gender (Figure 1) The macronutrient content
of the diets is described in Table 2.
Dietary treatments as well as laboratory analyses were blinded
to investigators and all animal procedures (23). In Experiment 1
and 2, preterm pigs were fed standard formula with or without
HMO for 5 days. In Experiment 1 (n = 44), 5 g/L 4-HMO
or maltodextrin (controls) were added to the formula, whereas
in Experiment 2 (n = 38), 7 g/L 25-HMO were supplemented
to account for the lower abundance of the major HMO used
in the 4-HMO blend (23); in Experiment 3 (11 days, n = 30),
preterm pigs were fed with 10 and 5 g/L 4-HMO for the first 4
days and up to 11 days, respectively; the control group received
ready-to-feed infant formula (RTF-IF, controls) without HMO
supplementation. The infant formula was chosen to include
a more translational aspect into the longer term experiment.
At the end of the experiments, pigs were anesthetized (Zoletil
50, zolazepam/tiletamin; Boehringer Ingelheim, Copenhagen,
Denmark), euthanized by injection with sodium pentobarbital,
and biological material was collected. Colonic content and urine
taken from the bladder were snap-frozen for determination
of HMO, colonic microbiota composition, and intestinal
permeability. Tissue samples were collected for evaluation of
NEC as reported previously (19). Collection of colonic contents
and urine could not be achieved from all animals in amounts
necessary for all analyses; thus, the number of samples analyzed
is given in the corresponding figures.
Evaluation of NEC and
Intestinal Permeability
Stomach, small intestine (proximal, middle, and distal regions),
and colon were evaluated for NEC lesions and given a score
from 1 (absence of macroscopic lesions), 2 (local hyperemia), 3
(hyperemia, milch hemorrhage, extensive edema), 4 (extensive
hemorrhage), 5 (local necrosis, and pneumatosis intestinalis)
to 6 (extensive necrosis and intramural gas cysts). NEC was
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FIGURE 1 | Experimental design for 5-day and 11-day experiments in preterm pigs.
defined as a score of ≥3 in any of the evaluated regions
(23). Intestinal permeability was determined by the lactulose
to mannitol ratio in urine. Pigs were fed 5% lactulose and 5%
mannitol (15 mL/kg body weight) 3 h prior to euthanasia, and
were fed half a bolus of their respective diets 1.5 h prior to
euthanasia. Urine was collected at euthanasia, and lactulose and
mannitol concentrations were analyzed spectrophotometrically
as described previously (24).
Analytical Procedures for
HMO Quantification
High-performance anion-exchange chromatography with
pulsed amperometric detection (HPAEC-PAD) was applied for
discrimination of stereoisomeric HMO, e.g., lacto-N-tetraose
(LNT) and LNnT as well as for identification and quantification
of HMO in urine and colonic contents using external standard
oligosaccharides (Carbosynth Ltd, Berkshire, UK; Dextra,
Reading, UK; Elicityl, Crolles, France) (25, 26). To verify the
presence of HMO determined by HPAEC-PAD, matrix-assisted
laser desorption ionization mass spectrometry (MALDI-TOF-
MS) was used as described (26). Briefly, samples (urine and
solubilized colon contents) were centrifuged after the addition
of pure water. For normalization of the amount of urinary
constituents applied to the extraction procedure, creatinine
concentration was determined colorimetrically (R&D Systems,
Heidelberg, Germany). Solid phase extraction with porous
graphitic carbon cartridges (for colonic contents: HyperSep-
96 Wells, 25mg; for urine: HyperSep Hypercarb 50mg;
Thermo Scientific, Bellefonte PA, USA) was performed via a
Hamilton Microlab Starlet liquid handling system (Hamilton
Robotics, Reno, NV, USA) or manually for urine samples. The
conditions for cartridge equilibration as well as the elution of
oligosaccharides have been described previously (25, 26).
After solid phase extraction, oligosaccharides were dried
overnight in a vacuum centrifuge and resuspended in water.
An HPAEC-PAD system (Dionex ICS-5000) equipped with a
CarboPac PA-1 and a guard column was operated using the
Chromeleon 6.80 software (ThermoFisher Scientific, Dreieich,
Germany). The running parameters at a constant flow rate of 0.5
mL/min were as follows: 0.1 mol/L sodium hydroxide from 0 to
15min, followed by a linear gradient up to 0.25 mol/L sodium
acetate in 0.1 mol/L sodium hydroxide for 87min. External
oligosaccharide standards were used for peak identification and
the area under the curves were determined. Individual 4-point
calibrations were used for quantification of oligosaccharides in
extracts from urine and colonic contents. Mass spectra from the
same samples in triplicate determinations were acquired using
an Ultraflex I instrument (Bruker Daltonics, Bremen, Germany).
Oligosaccharide profiles were acquired in positive-ion mode over
a mass range of m/z 340–3,200. Data acquisition and analysis
were performed by flexControl and flexAnalysis 3.0 software
(Bruker Daltonics, Bremen, Germany), respectively (25, 26).
Identification and Characterization
of Microorganisms
Colonic bacterial microbiota composition was determined by
tag-encoded 16S rRNA gene MiSeq-based high throughput
sequencing (Illumina, San Diego, CA, USA) as published recently
(27). Briefly, DNA was extracted from 0.5 g colon content using
the PowerSoil DNA Isolation Kit (MoBio Laboratories). The V3-
V4 region of the 16S rRNA gene was amplified with the universal
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TABLE 1 | HMO compositions in 4-HMO and 25-HMO blends.
No. Compounda Abbreviation Amount in 4-HMO
(g/100g blend)
Amount in 25-HMO
(g/100g blend)
1 2′Fucosyllactose 2′FL 61.9 18.7
2 Lacto-N-neo-tetraose LNnT 10.3 7.9
3 Lacto-N-tetraose LNT 14.4 7.9
4 6′Sialyllactose 6′SL 10.3 3.6
5 3-Fucosyllactose 3-FL – 12.1
6 Difucosyllactose DF-L – 2.7
7 Lacto-N-fucopentaose I LNFP I – 6.5
8 Lacto-N-fucopentaose II LNFP II – 2.7
9 Lacto-N-fucopentaose III LNFP III – 1.8
10 Sialyllacto-N-tetraose a LST a – 0.9
11 Sialyllacto-N-neo-tetraose c LST c – 2.7
12 3′Sialyllactose 3′SL – 3.7
13 Disialyllacto-N-tetraose DSLNT – 7.0
14–32 Other oligosaccharidesb – 3.1 8.6
Others (mainly salt) – 2.9
TOTAL 100.0 100.0
The abundances of each HMO are presented as a relative amount of the total measured area under the curve as determined by High Performance Anion Exchange Chromatography
with Pulsed Amperometric Detection (HPAEC-PAD) for each HMO.
a Compounds 1–13 (90% of all oligosaccharides in the 25-HMO blend).
b Compounds 14–32 (not quantified).
TABLE 2 | Composition of the formula used in Experiment 1–3.
Standard Formulaa RTF-IFb
Energy, kJ/L 4,115 3,400
Protein, g/L 73 29
Fat, g/L 59 40
Carbohydrates, g/L 42 84
Lactose, g/L - 36
Maltodextrin, g/L 46 45
Oligosaccharides, g/L –c –d
a Piglet formula mixed from Pepdite 2-0, Liquigen-MCT (SHS International, Liverpool, UK),
and Lacprodan DI-9224 (Arla Food Ingredients, Aarhus, Denmark).
b RTF-IF, ready-to-feed infant formula for preterm infants (Alprem, Clinic 1, Nestlé Nutrition
S.A., Barcelona, Spain).
c Supplemented with maltodextrin (control) or HMO [Experiment 1 (5-day): 5 g/L 4-HMO;
Experiment 2 (5-day): 7 g/L 25-HMO].
d With and without HMO supplementation [Experiment 3 (11-day): 10 g/L 4-HMO blend
during the first 4 days, then 5 g/L as in Experiment 1].
prokaryotic primers 515F (5′-GTGCCAGCMGCCGCGGTAA-
3′) and 806R (5′-GGACTACHVGGGTWTCTAAT-3′ in a first
PCR revealing amplicon lengths of 290 bp (28–30). In a second
PCR, adapters compatible with the Nextera Index Kit (Illumina)
where attached to the amplicons. After the amplification of
fragments with adapters and tags, these were purified and
clean constructs were quantified prior to library pooling, by
using a Qubit fluorometer (Invitrogen, Carlsbad, CA, USA).
The 2 × 250-bp sequencing reaction followed the standard
procedure of Illumina MiSeq for pair-end reads. After sequence
generation, the reads were demultiplexed and paired followed
by a clean-up step to truncate primers, remove low quality
sequences, and chimeras following the default settings of the
UPARSE pipeline. Operational taxonomic units (OTUs) were
picked with USEARCH at>97% sequences identity and classified
using Mothur (v.1.33.3) and the RDP database (31, 32). Uneven
sequencing depth was corrected using a zero-inflated Gaussian
distribution implanted in the R package of MetagenomeSeq (33).
Statistical Analysis
Statistical analyses were carried out using GraphPad Prism 6.0.1.3
(GraphPad Software); results were expressed as medians with
IQR (interquartile range, 10th−90th percentiles). D’Agostino
Pearson omnibus normality tests were used to determine whether
data sets were well-modeled by normal distribution. If necessary,
log transformation was used. As indicated, data were analyzed by
ANOVA or student t-test. Corrections for multiple comparisons
were made using the Holm-Sidak method. Differences were
considered significant at P < 0.05.
Associations were described by using Spearman’s or Pearson
correlation coefficients. Correlation analyses were shown as
correlation coefficient r with 95% confidence interval.
Taxonomic relative abundance data (OTUs >5%) were used
to calculate correlations between HMO consumption and fecal
bacteria abundance. A Spearman’s correlation was used to
describe associations. Differences between groups were assessed
using ANOVA and Tukey multiple-comparison test.
RESULTS
Identification and Characterization of HMO
To analyze oligosaccharides in theHMOblends as well as in urine
and colonic contents, we applied HPAEC-PAD and MALDI-
TOF-MS. In the complex 25-HMO blend (Table 1), 13 HMO
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were quantified, which, however, comprised almost 90% of all
HMO present (Figure 2A). In Figure 2B, exemplary MALDI-
TOF-MS spectra of urine from pigs fed a control formula or
a formula supplemented with 4-HMO are shown. The control
pig received a standard formula containing higher saccharides
(maltodextrin), which was reflected by hexose oligomers of
different lengths. For the pig receiving HMO, the mass-to charge
ratio (m/z) of 511, 656, and 730 represent 2′FL, 6′SL, and the
isomers LNT and LNnT deriving from the 4-HMO blend.
HMO in Colon Contents and Urine
Five-Day Supplementation of 4-HMO (Experiment 1)
or of 25-HMO (Experiment 2)
The total colonic HMO content was 46.9 (20.6–337.7) mg/g
dry weight and in urine 16.2 (3.3–48.8) mg/µmol creatinine
(Figure 3A). Large variations were observed in both the total
HMO concentrations and individual components of the 4-HMO
blend. There seemed to be no specificity in the HMO degradation
or absorption. The 25-HMO blend, designed to be closer to
that normally found in human milk than the 4-HMO was used
in Experiment 2. With the 25-HMO blend, the total colonic
HMO content was 9.8 (0–29.1) mg/g dry weight and in urine
56.6 (9.3–127.3) mg/µmol creatinine (Figure 3B). As with the 4-
HMOblend, supplementation with the 25-HMOblend revealed a
large individual variability in HMO excretion via colon contents
and urine. In contrast to 2′FL in both HMO blends, 3-FL was
metabolized differently. Whereas, the colon contents of 2′FL
varied greatly [0.9 (0–6.3) mg/g dry weight], the variation of the
3-FL excretion was small with only low amounts detectable in the
colon and urine [0.01 (0–0.9) mg/g dry weight and 0.5 (0–1.1)
FIGURE 2 | Analytical procedures comprising (A) high-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD). From the
complex HMO blend named 25-HMO, 13 compounds were used for quantification (comprise 90% of all oligosaccharides in this blend), and (B) matrix-assisted laser
desorption ionization mass spectrometry (MALDI-TOF-MS). The panels show a representative profile of urine from piglets from Experiment 1 fed the standard formula
without (left panel) and with (right panel) a 4-HMO blend. The mass-to-charge (m/z) values are given as nominal mass for [M+Na]+ ions.
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mg/µmol creatinine, respectively], indicating an almost complete
fermentation. LNFP I, one of the quantitatively major HMO in
the 25-HMOblend, also showed very low concentrations in colon
content [0.01 (0–0.09) mg/g dry weight]. Its structural isomers,
LNFP II and III, were present in much lower concentrations in
the 25-HMO blend, but were detectable in higher amounts in
colon contents than LNFP I. Compared to the low amount of 3-
FL in both colonic content and urine, LNFP I was low in colonic
content but showed a large individual variation in urine.
Eleven-Day Supplementation of the 4-HMO Blend
(Experiment 3)
In this 11 days lasting experiment, the HMO content in the colon
as well as in urine varied largely with an average of 13.8 (0–
160.6) mg/g dry weight and 21.4 (5.8–97.0) mg/µmol creatinine,
respectively (Figure 3C). Similar to the 5-day experiment, there
seemed to be no specificity in HMO metabolism as the same
proportions between the 4 HMO were found in colonic content
and urine after 11 days, however, some pigs showed higher
FIGURE 3 | Total and individual concentrations of human milk oligosaccharides (HMO) in colon contents (mg/g dry weight) and urine (mg/µmol creatinine) after (A)
5-day supplementation of 4-HMO or (B) 5-day supplementation of 25-HMO, and (C) after 11-day feeding of 4-HMO. Data are presented as box plots with median
and interquartile range (IQR, 10–90th percentiles).
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utilization than others. For example, if the concentration of 2′FL
was high in colon content and urine, then LNnT, LNT, and 6′SL
excretion was high in the same animal (Figure 4).
Colonic Microbial Compositions and
HMO Concentrations
Figure 5 shows the most prevailing bacterial genera. At the
phylum level, only Firmicutes were detected in the 5-day
experiment when preterm piglets were fed the 4-HMO blend,
with Clostridium, Enterococcus, and Lactobacillus being most
abundant (Figure 5A). When the complex 25-HMO blend was
supplemented within a 5-day period, only few more genera were
present. Again,Clostridium and Enterococcus accounted for more
than half of all bacteria (Figure 5B).
The 11-day supplementation of the 4-HMO blend revealed an
increasingly complex microbial colonization with Bacteroidetes,
Actinobacteria, Proteobacteria, Firmicutes, and Fusobacteria
(Figure 5C). In contrast to the 5-day experiments, Proteobacteria
was the most abundant phylumwith mainly Camphylobacter and
Helicobacter at the genera level. Furthermore, at the genus level,
some Bifidobacteria which are well-known for their abilities to
consume HMO, were detected in both HMO-fed and control
pigs, with only slightly higher proportions in HMO-fed piglets
compared to controls (P < 0.11). Nevertheless, an inverse
correlation was found for Bifidobacteria density and total HMO
concentrations in colon contents (P < 0.05). An even stronger
inverse correlation was found for 2′FL, but not for other
HMO (Figure 6). No correlation was found for Lactobacillus
and Bacteroides.
Correlation of HMO and Cumulative NEC
Score and Gut Permeability
Data for clinical outcomes and NEC scores for all 112 pigs
have been described previously (23). When comparing HMO
levels in the colonic content with the cumulative NEC score, and
HMO levels in urine with intestinal permeability, a significant
correlation (r = −0.764; P = 0.0033) was found for HMO in
colon content of pigs with NEC in the 5-day experiment receiving
the 25-HMO blend. This inverse association was also observed
at the individual HMO level for various single oligosaccharides.
However, there was no significant correlation between HMO
levels in urine and intestinal permeability (Table 3).
DISCUSSION
We investigated effects of infant formula supplemented with
complexHMOmixtures in a preterm pigmodel.We documented
the metabolism of HMO from blends that either contained the
FIGURE 4 | Excretion of total HMOs and individual HMOs from the 4-HMO blend containing 2′FL, LNnT, LNT, and 6′FL via the colon and urine. Different color dots
represent HMO concentrations from different pigs with higher HMO excretions.
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FIGURE 5 | Relative bacterial abundances of taxa in the colonic microbiota at the genus level. Bacterial genera detected in colon content of pigs from (A) Experiment
1 (4-HMO) for (5 days), (B) Experiment 2 (25-HMO for 5 days), and (C) Experiment 3 (4-HMO) for (11 days). Data from control pigs are shown as white bars and those
from pigs receiving HMO blends as gray bars. Data are presented as box plots with median and interquartile range (IQR, 10–90th percentiles). Only phyla with relative
abundance >5% were included.
major HMO (4-HMO blend) or the most abundant HMO (25-
HMO blend) at a ratio of neutral and acidic oligosaccharides
of about 80:20 which has been reported for human milk (1).
Analyzing urine and feces across three different experiments, we
found large individual variations in HMO excretion. This was
particularly the case in the 4-days experiment (Figure 4) whereas
after 11 days this large variation was markedly reduced. Due to
the low number of individual samples, it is unclear at themoment
whether the excretion is related to the relative distribution of
HMO in the formula diet.
For 3-FL and LNFP I, there seems to be a structure-specific
metabolism of this single HMO. Their concentration in the
colon was very low although they belonged to the major HMO
components in the 25-HMO blend. LNFP I is typically found in
human milk of secretors (about 70–80% of the population) and
shares similar functional epitopes with 2′FL which is currently
considered to be a highly potent HMO. 3-FL regularly occurs
in human milk, but has until now received limited attention
as compared to its structural isomer 2′FL (25). In addition,
the linkage of fucose on C-atom 2 of the galactose moiety
of 2′FL turns it into a structure with a high potential as an
anti-adhesive and anti-inflammatory component. Although the
secretor-specific α1-2-fucose linkage is missing in 3-FL, an in
vitro inhibiton of Norovirus binding has been reported for both
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FIGURE 6 | Scatter plots of total and individual human milk oligosaccharides (HMO) and Bifidobacteria in colon content from preterm pigs fed the 4-HMO blend for
11 days (Experiment 3). Correlation of Bifidobacteria abundance with (A) total HMO level in colon content and (B) with 2′fucosyllactose (FL). Spearman’s coefficients
(r) and p-values (P) are shown.
TABLE 3 | Correlation of total HMOs in colon and urine with NEC and intestinal
permeability, respectively.
No. Experiment 1
(5 days, 4-HMO)
[piglets, n]
Experiment 2
(5 days, 25-HMO)
[piglets, n]
Experiment 3
(11 days, 4HMO)
[piglets, n]
NECa
All piglets −0.318nsc [17] −0.722ns[18] −0.316ns [16]
NEC −0.866ns [4] −0.764**e [13] −0.476ns [9]
No NEC −0.241ns [13] −0.001ns [5] −0.722ns [7]
PERb
All piglets 0.121ns [8] −0.318ns [11] 0.400ns [4]
NEC n.d.d [2] −0.866ns [3] n.d. [2]
No NEC −0.116 ns [6] −0.241ns [8] n.d. [2]
a Cumulative NEC score: a score of≥3 in any of the evaluated regions (stomach, proximal,
middle, distal small intestine or colon) was defined as NEC.
b Permeability: lactulose and mannitol contents were analyzed in urine and lactulose to
mannitol concentration ratio was used as an indicator of intestinal permeability.
c Significance was given at **P < 0.05 (ns = not significant).
d n.d. = not determined. The limited sample size hampered detail statistical evaluation for
subgroups.
e Significant correlation for 2′FL (r=−0.67; P= 0.01), difucosyllactose (DF-L) (r=−0.69;
P = 0.008), LNFP II (r = −0.72; P = 0.0039), LNT (r = −0.65; P = 0.0076), LNnT (r =
−0.59; P = 0.0011) and disialyl-LNT (DSLNT) (r = −0.64; P = 0.03), but not for 3-FL,
LNFP I, LNFP III, sialyl-LNT (LST) a, LST b, 3′SL and 6′SL.
isomers (34). While 3-FL might be primarily utilized by gut
microbiota, as it is low in both, colon content and in urine, LNFP
I seems to selectively be taken up and excreted in relatively large
amounts in urine (Figure 3B). Another interesting observation
regarding 2′FL is that whenever the fecal excretion of 2′FL was
high, the excretion of all other HMOs in the same animal was
high as well suggesting an overall low microbial activity.
Regarding disease prevention, the acidic HMO, DSLNT, had
remarkable NEC-preventing effects in newborn rats (19). In
our preterm pigs, DSLNT was neither clearly related to NEC
nor to bacterial colonization despite the high supplementation
(about 7% of the 25-HMO blend). These differences could reflect
the immaturity of the gut and its bacterial colonization in
preterm pigs, a prevailing dysbiosis, which is rather common in
cesarean born preterm pigs, with unknown severity, or species-
specific differences.
Large individual variability in fecal excretion of HMO have
also been found for term and preterm infants fed human milk
(26, 35, 36). A gradual change in the fecal oligosaccharide profile
in breastfed infants during the first six months postpartum has
been reported, without LNT being identified in fecal samples
(37). This is in contrast to our previous data (26, 35, 36,
38), where we detected LNT in all fecal samples from human
term-born infants whenever HMO were excreted. In infants,
there is a large variation in the amount and pattern of HMO
excretions, ranging from large amounts to no excretion at all.
The reason for this divergence is not known but may be related
to a different gut microbial composition and, hence, a different
HMO metabolism in the intestinal lumen. For example, LNT,
the major core structure of HMO, was initially considered
to be a unique growth promoter of Bifidobacterium longum
subsp. infantis although others, e.g., Bifidobacteria breve also use
intact LNT (39, 40). In future studies, it is important to relate
HMO metabolism in the gut lumen to subspecies level. In the
present study we observed that microbial colonization in the
two 5-day experiments was limited to Firmicutes (Experiment 1)
and relatively low numbers of Actinobacteria and Bacteriodetes
(Experiment 2), consisting mainly of Clostridium (cluster I)
and Enterococcus. In Experiment 3 (11-day supplementation
of the 4-HMO blend), more bacterial phyla were found, with
Proteobacteria (mainly Campylobacter and Helicobacter) as the
predominant phylum. Bifidobacteria were also detected but in
lower abundance. There were no changes in the microbial
colonization of the pigs when supplementing formula with the
4-HMO blend. The high abundance of Proteobacteria in the
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11-day experiment is in agreement with observations in a study
with preterm infants who were fed formula supplemented with
HMO from pooled human milk (no specification of HMO were
given) (41). The authors report low levels of Bifidobacteria and no
Lactobacilli, concomitantly with increasing numbers ofClostridia
and an unexpected trend toward an increase in Proteobacteria
in both groups. Although the interpretation of the data from
our piglets is difficult due to the large individual variation, the
presence of Bifidobacteria, although low in total numbers, was
correlated with total HMO contents, and specifically with 2′FL
levels in colonic content. The importance of 2′FL particularly
for Bifidobacteria through the interaction with a newly identified
ABC transporter as a key genetic factor for the utilization of
2′FL and other fucosylated oligosaccharides has been thoroughly
discussed by Matsuki et al. (42). This could be important, as
recent reports indicated a strong association of the secretor
genotype with the composition of Bifidobacteria in the human
intestine (43, 44).
In conclusion, we found that (i) all pigs receiving HMO
containing diets excreted these HMO via the colon and urine, but
individual variations were large. This data resemble the situation
in human infants with no clear excretion pattern neither in term
nor in preterm infants; (ii) HMO supplemenation was not related
to NEC, bacterial colonization or intestinal permeability; (iii)
the 5-day supplementation of the complex 25-HMO blend led
to low concentrations of 3-FL and LNFP I in colonic contents,
indicating a preferred utilization of these two HMO; (iv) In
colon, only the abundance of Bifidobacteria, although low in
total numbers compared to other microorganisms, correlated
with total HMO in colon content and specifically with 2′FL, (v)
Increasing the HMO supplementation period to 11 days lowered
the fecal excretion of HMO. Thus, intestinal immaturity, together
with delayed bacterial colonization and low bacterial diversity,
may lead to a different metabolic fate of HMO during the
first 1–2 weeks after preterm birth. A sufficient gastrointestinal
maturation may be required to observe clear benefits of HMO,
both locally in the gut and beyond.
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